论文部分内容阅读
目的观察厄贝沙坦和苯磺酸氨氯地平片联合用药对治疗糖尿病肾病伴高血压的临床疗效。方法糖尿病肾病伴高血压患者90例,随机将其分为三组,分别为观察组、对照一组和对照二组,每组30例。对照一组患者给予厄贝沙坦160 mg/d,对照二组给予苯磺酸氨氯地平片6 mg/d,观察组患者给予厄贝沙坦160 mg/d联合苯磺酸氨氯地平片6 mg/d。三组患者均治疗1个疗程(即3个月)之后观察三组患者的临床疗效并进行对比分析。结果所有患者治疗1个疗程之后血压均比治疗前有显著降低,观察组和对照二组患者的24 h尿蛋白含量均显著降低,而对照一组患者的24 h尿蛋白含量降低不明显,观察组患者的血压和24 h尿蛋白含量比对照一组和对照二组患者降低的都要显著,差异具有统计学意义(P<0.05)。结论苯磺酸氨氯地平片在治疗糖尿病肾病伴高血压方面比厄贝沙坦更有效,但是两药联合使用收到的临床疗效最好。
Objective To observe the clinical efficacy of irbesartan and amlodipine besylate in the treatment of diabetic nephropathy with hypertension. Methods 90 cases of diabetic nephropathy with hypertension were randomly divided into three groups: observation group, control group and control group, with 30 cases in each group. Control group of patients given irbesartan 160 mg / d, control two groups were given amlodipine besylate tablets 6 mg / d, the observation group were given irbesartan 160 mg / d combined with amlodipine besylate tablet 6 mg / d. Three groups of patients were treated for a course of treatment (ie 3 months) after the observation of three groups of patients with clinical efficacy and comparative analysis. Results All patients underwent a course of treatment after the blood pressure was significantly lower than before treatment, the observation group and control two groups of patients with 24 h urinary protein were significantly reduced, while the control group of 24-hour urine protein content was not significantly reduced observed The blood pressure and 24 h urinary protein in the patients in the two groups were significantly lower than those in the control group and the control group (P <0.05). Conclusion Amlodipine besylate tablets are more effective than irbesartan in the treatment of diabetic nephropathy with hypertension, but the combination of the two drugs has the best clinical efficacy.